Global Polymer Drug Conjugates Market

Report ID : 1316 | Published : 2022-07-12 | Pages: | Format: PDF/EXCEL

The market size of the Global Polymer Drug Conjugates Market is predicted to show an 32.7% CAGR during the forecast period.

Nano-sized pharmaceuticals known as polymer-drug conjugates are utilised to treat cancer and hepatitis. Polymers that are sensitive to certain enzymes prevalent in sick tissue are now being developed. Enzymatic activity and acidity in polymer-drug conjugates can degrade conventional polymers like cellulose and chitin. The Polymer Drug Conjugates Market is expected to expand rapidly during the forecast period, owing to strong growth in the pharmaceutical industry, particularly in the United States, and heavy investments in medical R&D, which has resulted in the development of technologically advanced medical devices and equipment. Since medical polymers are widely used in the production of pharmaceutical medications, substantial growth in the pharmaceutical sector in recent years has resulted in an increase in demand for medical polymers, which will boost industry share during the projected period.

The absence of established and improved preclinical or clinical approaches for evaluating polymer-drug conjugate stability, tumour penetration, metabolism, and toxicity is hindering polymer-drug conjugate market expansion. With the restricted use of polymer-drug conjugates, the market for polymer-drug conjugates is expected to grow slowly. The benefits of minimally invasive surgery, which include shorter hospital stays, faster recovery times, and minor bleeding and discomfort, increase their appeal. Because of the rising preference for these techniques over traditional surgery, the use of specific medical equipment has decreased, potentially hindering market growth.

Market Segmentation:

The Polymer Drug Conjugates Market is segmented on the basis of product type and application. Based on product type, the market is segmented as Polymer-Dox Conjugates, Polymer-Paclitaxel Conjugates, Polymer-Camptothecin Conjugates, and Polymer-Platinate Conjugates. Based on application, the market is segmented as Cancer Treatment, Leukemia, Hepatitis, and Others.

Based on product type, the Polymer-Paclitaxel Conjugates segment is accounted as a major contributor in the Polymer Drug Conjugates Market.

Paclitaxel, derived from the bark of the Pacific Yew tree, is one of the most potent anticancer drugs available for the treatment of ovarian, breast, and lung cancer. Currently, commercial-scale paclitaxel bulk is manufactured from the Taxus chinensis cell line. Polymer paclitaxel conjugates gain ground in three areas robust conjugation chemistry, ease of large-scale manufacturing, and simple formulation. With their sluggish elimination from the kidney and improved penetration and retention effects, polymer-paclitaxel conjugates are projected to have a longer plasma half-life and a high tumor accumulation. Paclitaxel, on the other hand, has low bioavailability due to its low water solubility.

Based on application, the Leukemia segment is accounted as a major contributor to the Polymer Drug Conjugates Market.

Leukemia is a hematologic malignancy that primarily affects adults and the bone marrow, lymphatic system, and blood cells. The factors such as exposure to pesticides and paint, smoking history, and occupational exposure to chemicals are some major contributors to the growth of leukemia cases. Traditional cancer therapies, such as surgery, chemotherapy, and radiation, may result in inadequate cancer eradication or the destruction of normal cells. Nanotechnology addresses the shortcomings of these traditional approaches by serving as a guide in surgical tumor removal, directly targeting chemotherapies, and being selective to malignant cells. 5 This innovative device can lower the risk to the patient while also increasing the likelihood of survival, thus increasing the use of polymer drugs conjugate. Growing R&D activities and technological development are projected to provide a variety of new opportunities that will benefit the growth of the Polymer Drug Conjugates Market during the forecast period.

The North American Polymer Drug Conjugates Market holds a major revenue share in the region.

North America is likely to hold a chief position in the global polymer-drug conjugates market because of the rising number of clinical trials in the United States. The region's ageing population and the prevalence of chronic diseases have increased the demand for medical devices. This is projected to drive demand for medical polymers in equipment manufacturing over the forecast period. Rising demand for medical polymers in pharmaceutical medications and the rapid expansion of pharmaceutical enterprises in Mexico and Canada are expected to drive growth even further. Increasing government investments in the healthcare sector and an expanding home healthcare market are expected to boost demand for medical equipment over the forecast period, and the Polymer Drug Conjugates Market would be positively influenced.

Competitive Landscape

The key players in the Polymer Drug Conjugates Market have shifted their focus towards bio-based components for product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance product portfolio and strengthen their market footprint across the globe. Some of the major key players in the Polymer Drug Conjugates Market are 3S Bio, Abeona Therapeutics, Abramson Cancer Center, Access Pharmaceuticals, Adama, Eyetech, Ferring, Flamel Technologies, Genentech, GlaxoSmithKline, Gowan, Gynecologic Oncology Group Foundation, JenKem Technology, Landec, and Lipotek.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Polymer Drug Conjugates Market Snapshot

Chapter 4. Global Polymer Drug Conjugates Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis

5.1. By Product Type & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Product Type:

5.2.1. Polymer-Dox Conjugates

5.2.2. Polymer-Paclitaxel Conjugates

5.2.3. Polymer-Camptothecin Conjugates

5.2.4. Polymer-Platinate Conjugates

Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis

6.1. By Application & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Application:

6.2.1. Cancer Treatment

6.2.2. Leukmia

6.2.3. Hepatitis

6.2.4. Others

Chapter 7. Polymer Drug Conjugates Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Polymer Drug Conjugates Market revenue (US$ Million) estimates and forecasts By Product Type, 2020-2030

7.1.2. North America Polymer Drug Conjugates Market revenue (US$ Million) estimates and forecasts By Application, 2020-2030

7.1.3. North America Polymer Drug Conjugates Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

7.2. Europe

7.2.1. Europe Polymer Drug Conjugates Market revenue (US$ Million) By Product Type, 2020-2030

7.2.2. Europe Polymer Drug Conjugates Market revenue (US$ Million) By Application, 2020-2030

7.2.3. Europe Polymer Drug Conjugates Market revenue (US$ Million) by country, 2020-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Polymer Drug Conjugates Market revenue (US$ Million) By Product Type, 2020-2030

7.3.2. Asia Pacific Polymer Drug Conjugates Market revenue (US$ Million) By Application, 2020-2030

7.3.3. Asia Pacific Polymer Drug Conjugates Market revenue (US$ Million) by country, 2020-2030

7.4. Latin America

7.4.1. Latin America Polymer Drug Conjugates Market revenue (US$ Million) By Product Type, (US$ Million)

7.4.2. Latin America Polymer Drug Conjugates Market revenue (US$ Million) By Application, (US$ Million)

7.4.3. Latin America Polymer Drug Conjugates Market revenue (US$ Million) by country, 2020-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Polymer Drug Conjugates Market revenue (US$ Million) By Product Type, (US$ Million)

7.5.2. Middle East & Africa Polymer Drug Conjugates Market revenue (US$ Million) By Application, (US$ Million)

7.5.3. Middle East & Africa Polymer Drug Conjugates Market revenue (US$ Million) by country, 2020-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles 

8.2.1. 3S Bio

8.2.2. Abeona Therapeutics

8.2.3. Abramson Cancer Center

8.2.4. Access Pharmaceuticals

8.2.5. Adama

8.2.6. Eyetech

8.2.7. Ferring

8.2.8. Flamel Technologies

8.2.9. Genentech

8.2.10. GlaxoSmithKline

8.2.11. Gowan

8.2.12. Gynecologic Oncology Group Foundation

8.2.13. JenKem Technology

8.2.14. Landec

8.2.15. Lipotek

8.2.16. Other Prominent Players

Segmentation of Polymer Drug Conjugates Market-

By Product Type

  • Polymer-Dox Conjugates
  • Polymer-Paclitaxel Conjugates
  • Polymer-Camptothecin Conjugates
  • Polymer-Platinate Conjugates

By Application

  • Cancer Treatment
  • Leukemia
  • Hepatitis
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients